Drug manufacturers to focus on China and Japan, where penetration is low and innovation continues to emerge, Morgan Stanley says.
‘China’s Ozempic’ may vie with Eli Lilly, Novo Nordisk for global weight-loss drug market
RELATED ARTICLES
Hong Kong man arrested for allegedly driving school bus under influence of drugs
Tower of peace or sin? Why China demands that a Japanese wartime monument be demolished
AMD chief Lisa Su visits Lenovo in Beijing as US hints at easing chip curbs
